Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer

European Journal of Cancer

Volumn 39, Issue 3, 2003, Pages 317-320

  Kerbrat, P ^f   Dieras, V ^a   Pavlidis, N ^b   Ravaud, A ^c   Wanders, J ^d   Fumoleau, P ^e  

^a INSTITUT CURIE   (France)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUT BERGONIÉ   (France)

^d NDDO Oncology   (Netherlands)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f NONE

Author keywords

Breast cancer; Dolastatin; LU 103793; Phase II

Indexed keywords

BILIRUBIN; CEMADOTIN; DOLASTATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEVER; HEADACHE; HEART; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER; MALAISE; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TIME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOPEPTIDES;

EID: 0037306134     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00531-2     Document Type: Article

References (7)

1. Schwartsmann G., Brondani Da Rocha A., Berlinck R., Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2:2001;221-225.
2. Bai R., Friedman S.J., Pettit J.R., Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interactions with tubulin and effects on cellular microtubules. Biochem. Pharmacol. 43:1992;2637-2645.
3. Smith P., Nelson C., Janssen B.et al. Preclinical antitumour activity of a novel water-soluble dolastatin 15 analogue (LU 103793). Proc Am Assoc Cancer Res. 36:1995;393. (abstract 2345).
4. Vallalona-Calero M., Baker S.D., Hammond L.et al. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU 103793 in patients with advanced solid malignancies. J Clin Oncol. 14:1998;2770-2779.
5. Perez E.A., Fishkin P.A., Hillman D.W.et al. Dolastatin 10 in patients with advanced breast cancer, an NCCTG study. 23rd Annual San Antonio Breast Cancer Symposium. Abstract:2000;350.
6. Krug L.M., Miller W.A., Kalemkerian G.P.et al. Phase II study of dolastatin 10 in patients with advanced non-small cell lung cancer. Ann Oncol. 11:2000;227-228.
7. Smyth J., Bonneterre M.E., Schellens J.et al. Activity of the analogue, LU 103793, in malignant melanoma. Ann Oncol. 12:2001;509-511.